We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DXRX Diaceutics Plc

0.00 (0.00%)
22 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Diaceutics Plc LSE:DXRX London Ordinary Share GB00BJQTGV64 ORD GBP0.002
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 103.50 103.00 104.00 104.00 103.00 103.00 7,298 08:00:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Testing Laboratories 19.5M 724k 0.0086 120.35 87.43M

Diaceutics PLC Exercise of Warrant & Total Voting Rights

25/01/2024 1:16pm

RNS Regulatory News

RNS Number : 9506A
Diaceutics PLC
25 January 2024

Diaceutics PLC - Exercise of Warrant & Total Voting Rights


Belfast and London, 25 January 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to pharma and biotech companies, announces that it has received notification for the exercise of warrants over 177,915 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at an exercise price of £0.76 per share, providing the Company with proceeds of £135,215 ("Warrant Exercise").


Application has been made to the London Stock Exchange to admit the 177,915 new ordinary shares resulting from the Warrant Exercise to trading on AIM ("Admission"), which is expected to occur on at 8:00 am tomorrow 26 January 2024.  The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Warrant Exercise completes all outstanding warrants.


Following Admission, the total issued share capital of the Company will consist of 84,679,305 Ordinary Shares. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. 




Diaceutics PLC   

Ryan Keeling, Chief Executive Officer 

Tel: +44 (0)28 9040 6500 

Nick Roberts, Chief Financial Officer 

Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison 

Nick Harland 

Kate Hanshaw

Alma Strategic Communications

Tel: +44(0)20 3405 0205 

Caroline Forde

Matthew Young

Kinvara Verdon


About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.


We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®







This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

1 Year Diaceutics Chart

1 Year Diaceutics Chart

1 Month Diaceutics Chart

1 Month Diaceutics Chart

Your Recent History

Delayed Upgrade Clock